Table 2.

Additional of prognostic value of gene expression signatures on top of Ki67 or IHC and vice versa for all, ER⁺/LN⁻, ER⁺/LN⁺, ER⁻ patients based on likelihood ratio (LR-χ²) test in cohort 1

Added prognostic value of gene expression signatures on top of Ki67/IHC and vice versa, cohort 1
	All (n = 379, events = 135)		ER+/LN− (n = 104, events = 26)		ER+/LN+ (n 167, events = 74)		ER− (n = 103, events = 35)
Model	LR-χ2	P	LR-χ2	P	LR-χ2	P	LR-χ2	P
Univariate
Ki67	8.8	0.003	2.4	0.123	7.8	0.005	0.1	0.767
IHC	22.9	<0.001	3.0	0.227	9.8	0.007	6.2	0.012
	LR-Δχ2	P	LR-Δχ2	P	LR-Δχ2	P	LR-Δχ2	P
G.Sigs addition to Ki67/IHC
Ki67 + G.Sigs
Ki67 + GGI	2.0	0.158	0.9	0.353	5.4	0.019	3.6	0.058
Ki67 + 70-Gene	1.4	0.232	1.0	0.319	6.4	0.011	0.2	0.699
Ki67 + RS	12.8	0.001	4.2	0.125	9.6	0.008	1.0	0.328
Ki67 + CCS	1.7	0.422	0.1	0.965	6.0	0.048	3.2	0.206
Ki67 + PAM50	20.7	<0.001	6.3	0.178	12.5	0.013	6.2	0.182
IHC + G.Sigs
IHC + GGI	2.5	0.113	0.7	0.395	5.4	0.020	1.2	0.281
IHC + 70-Gene	1.9	0.171	1.1	0.283	6.0	0.014	0	0.882
IHC + RS	12.9	0.001	4.1	0.127	9.2	0.010	0.4	0.517
IHC + CCS	2.4	0.299	0.1	0.955	6.3	0.043	0.4	0.819
IHC + PAM50	11.7	0.020	6.2	0.187	11.1	0.025	1.8	0.765
Ki67/IHC addition to G.Sigs
G.Sigs + Ki67
GGI + Ki67	2.2	0.140	0.5	0.488	0.9	0.346	0.9	0.351
70-Gene + Ki67	2.4	0.121	3.4	0.063	1.0	0.308	0.2	0.681
RS + Ki67	0.5	0.476	0.1	0.758	1.2	0.270	0.1	0.810
CCS + Ki67	2.7	0.098	1.4	0.242	0.5	0.469	1.0	0.318
PAM50 + Ki67	1.9	0.166	4.2	0.040	0.1	0.753	0.4	0.541
G.Sigs + IHC
GGI + IHC	16.9	<0.001	0.9	0.629	2.9	0.232	4.6	0.032
70-Gene + IHC	17.1	<0.001	4.1	0.128	2.7	0.257	6.2	0.012
RS + IHC	14.8	0.002	0.7	0.718	2.9	0.234	5.7	0.017
CCS + IHC	17.6	<0.001	2.0	0.372	2.8	0.240	4.4	0.036
PAM50 + IHC	7.1	0.068	4.6	0.098	0.8	0.660	2.1	0.146

Abbreviations: LR-χ², likelihood ratio; LN, lymph node metastasis; IHC, immunohistochemical markers; events, number of deaths from breast cancer.